Safety and clinical outcomes of GT0918 (Proxalutamide), a potent androgen receptor (AR) blocker, in patients with mCRPC progressing on standard (SoC) and experimental therapies: Phase I/II trial. Nicholas

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2019
This article has no abstract
Epistemonikos ID: 44b500c656295f9cf1e98df4ffa33741620f7d7f
First added on: Feb 11, 2025